MedTrace Logo

Pharmacodynamics of Omiganan (CLS001) in Patients With Atopic Dermatitis

NCT02456480 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2016-07-28

No results posted yet for this study

Summary

To assess the pharmacodynamics, safety/tolerability, and efficacy of omiganan in patients with mild to moderate atopic dermatitis (AD).

Conditions

Interventions

DRUG

CLS001

topical gel

DRUG

Vehicle

topical gel

Sponsors & Collaborators

  • Maruho Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • J. (Koos) Burggraaf, MD, PhD · Centre for Human Drug Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2015-11-30
Completion
2015-11-30

Countries

  • Netherlands

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02456480 on ClinicalTrials.gov